Ketorolac Tromethamine
Product Images NDC 51662-1488

9 FDA label images from Hf Acquisition Co Llc, Dba Healthfirst · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 51662-1488). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse 1 (Adverse 1)

Adverse 1 (Adverse 1)
A data table listing gastrointestinal and other experiences potentially related to the drug KETOROLAC TROMETHAMINE. It categorizes symptoms such as abdominal pain, constipation/diarrhea, dyspepsia, flatulence, and GI ulcers among gastrointestinal experiences, and symptoms like abnormal renal function, anemia, dizziness, and hypertension under other experiences.*
FDA Label Image

Adverse 2 (Adverse 2)

Adverse 2 (Adverse 2)
A data table titled 'Incidence of Clinically Serious G.I. Bleeding as Related to Age, Total Daily Dose, and History of G.I. Perforation, Ulcer, Bleeding (PUB) after up to 5 Days of Treatment with Ketorolac Tromethamine Injection.' It presents percentages of serious gastrointestinal bleeding by age group and total daily dose for adult patients with and without a history of PUB.*
FDA Label Image

Boxed Warning (Boxed Warning)

Boxed Warning (Boxed Warning)
Drug facts and warnings panel for Ketorolac Tromethamine, detailing boxed warnings about gastrointestinal, cardiovascular, and bleeding risks, contraindications for specific patient populations, hypersensitivity reactions, administration routes, dosage, and instructions aimed at healthcare providers.*
FDA Label Image

Clinical 1 (Clinical 1)

Clinical 1 (Clinical 1)
Data table presenting approximate average pharmacokinetic parameters (mean ± SD) for ketorolac tromethamine following oral, intramuscular, and intravenous bolus doses. Parameters include bioavailability, time to maximum concentration (Tmax), maximum concentration (Cmax), minimum concentration (Cmin), average concentration (Cavg), and volume of distribution (Vβ) across different dosages in mg and routes of administration.*
FDA Label Image

Clinical 2 (Clinical 2)

Clinical 2 (Clinical 2)
A pharmacokinetic data table showing percentages of dose metabolized, excreted in feces and urine, plasma protein binding, and study details for ketorolac tromethamine. It includes notes on derived data from pharmacokinetic studies in volunteers and explanations of plasma concentration terms and volume of distribution.*
FDA Label Image

Clinical 3 (Clinical 3)

Clinical 3 (Clinical 3)
Table presenting the influence of age, liver, and kidney function on the clearance and terminal half-life of Ketorolac Tromethamine following intramuscular (IM) and oral administration in adult populations. Data include total clearance (L/h/kg) and terminal half-life in hours across different subject groups: normal subjects, healthy elderly, hepatic dysfunction, renal impairment, and renal dialysis patients.*
FDA Label Image

Serialized Labeling (Serialized Labeling)

Serialized Labeling (Serialized Labeling)
KETOROLAC TROMETHAMINE injection, USP in a 2 mL single-dose vial with a strength of 60 mg/2 mL (30 mg/mL). The label shows the NDC 72266-119-01 and indicates it is for intramuscular use only. Distributed by HF Acquisition Co LLC, DBA HealthFirst, Mukilteo, WA.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of Ketorolac Tromethamine, showing the molecular arrangement of the active ingredient with labeled atoms and bonds.*
FDA Label Image

Vial Label (Vial Label)

Vial Label (Vial Label)
Label for Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL) in a 2 mL single-dose vial. The label states it is for intramuscular use only and is distributed by Fosun Pharma USA Inc. It includes a barcode, lot, and expiration date fields, and notes the product is made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.